HKD3.89
1.52% today
Hong Kong, Apr 03, 10:08 am CET
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Sino Biopharmaceutical Stock price

HKD3.89
+0.69 21.56% 1M
+0.03 0.78% 6M
+0.69 21.56% YTD
+0.97 33.22% 1Y
-0.65 14.32% 3Y
-3.14 44.64% 5Y
+1.48 61.48% 10Y
Hong Kong, Closing price Thu, Apr 03 2025
-0.06 1.52%
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Key metrics

Market capitalization HKD72.43b
Enterprise Value HKD78.74b
P/E (TTM) P/E ratio 37.62
EV/Sales (TTM) EV/Sales 2.52
P/S ratio (TTM) P/S ratio 2.31
P/B ratio (TTM) P/B ratio 2.18
Dividend yield 1.52%
Last dividend (FY23) HKD0.06
Revenue growth (TTM) Revenue growth 7.63%
Revenue (TTM) Revenue HKD31.30b
EBIT (operating result TTM) EBIT HKD6.76b
EPS (TTM) EPS HKD0.11
P/E forward 22.32
P/S forward 2.11
EV/Sales forward 2.29
Show more

Is Sino Biopharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Sino Biopharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Sino Biopharmaceutical forecast:

24x Buy
92%
2x Hold
8%

Analyst Opinions

26 Analysts have issued a Sino Biopharmaceutical forecast:

Buy
92%
Hold
8%

Financial data from Sino Biopharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
31,296 31,296
8% 8%
100%
- Direct Costs 5,785 5,785
4% 4%
18%
25,510 25,510
8% 8%
82%
- Selling and Administrative Expenses 11,826 11,826
6% 6%
38%
- Research and Development Expense 5,518 5,518
13% 13%
18%
8,166 8,166
9% 9%
26%
- Depreciation and Amortization 1,402 1,402
25% 25%
4%
EBIT (Operating Income) EBIT 6,764 6,764
6% 6%
22%
Net Profit 1,940 1,940
25% 25%
6%

In millions HKD.

Don't miss a Thing! We will send you all news about Sino Biopharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO S Tse
Employees 24,379
Founded 2000
Website www.sinobiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today